샘플 요청 목록

 카트 문의
시장보고서
상품코드
1563846

세계의 혈액 검사 시장

Blood Screening
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 158 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

혈액 검사 세계 시장, 2030년까지 38억 달러에 달할 것으로 예상

2023년 26억 달러로 추정되는 세계 혈액 검사 시장은 2023-2030년 동안 연평균 5.6%의 성장률을 기록하여 2030년에는 38억 달러에 이를 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 핵산 검사(NAT)는 CAGR 5.3%를 기록하여 분석 기간이 끝날 때까지 17억 달러에 도달할 것으로 예상됩니다. 효소 결합 면역 흡착 분석법(ELISA) 분야의 성장률은 분석 기간 동안 6.2%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 추정됩니다.

미국 시장은 6억 9,770만 달러로 추정, 중국은 CAGR 9.1%로 성장 전망

미국 혈액 검사 시장은 2023년 6억 9,770만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2023-2030년의 분석 기간 동안 9.1%의 연평균 복합 성장률(CAGR)을 나타내고, 2030년에는 8억 3,140만 달러 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 각각 1.9%와 6.0%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 CAGR 3.0%로 성장할 것으로 예상됩니다.

세계 혈액 검사 시장 - 주요 동향 및 촉진요인 요약

혈액 검사가 안전한 건강 관리에 필수적인 이유는 무엇인가?

혈액 검사는 수혈, 장기 이식, 진단 목적으로 사용되기 전에 혈액 샘플에서 감염 인자, 유전 질환 및 기타 건강 상태를 감지하도록 설계된 건강 관리의 중요한 과정입니다. 이 선별 과정은 혈액 및 혈액 제제의 안전성을 보장하고 HIV, 간염, 매독과 같은 감염병을 예방하는 데 필수적입니다. 혈액 검사는 또한 암, 유전성 유전 질환 등의 조기 발견에 중요한 역할을 하여 적시에 개입하고 치료할 수 있도록 합니다. 혈액 선별 검사의 정확성과 신뢰성은 환자의 안전과 공중 보건에 직접적인 영향을 미치기 때문에 가장 중요합니다. 전 세계적으로 안전한 혈액제제에 대한 수요가 지속적으로 증가함에 따라 혈액 검사는 환자를 보호하고 치료의 효과를 보장하는 현대 의료의 필수 요소로 자리매김하고 있습니다.

기술의 발전은 혈액 검사 과정을 어떻게 변화시켰을까?

기술의 발전으로 혈액 검사 분야는 더 빠르고, 더 정확하고, 더 종합적인 검사 방법으로 변모하고 있습니다. 기존 혈액 검사는 수작업과 기본적인 혈청학적 검사에 의존해 왔으며, 이는 효과적이지만 범위가 제한적이고 결과가 나오기까지 며칠이 걸리기도 했습니다. 자동 검사 시스템과 분자진단학의 도입으로 혈액 검사의 속도와 정확도가 비약적으로 향상되었습니다. 핵산 검사(NAT)와 같은 기술을 통해 바이러스 및 세균 병원체를 조기에 발견할 수 있게 되어 수혈로 인한 감염 위험을 줄일 수 있게 되었습니다. 또한, 대량 혈액 샘플을 보다 효율적으로 처리할 수 있는 고처리량 스크리닝 시스템의 개발은 현대 의료 시설의 요구에 부응하는 데 매우 중요한 역할을 하고 있습니다. 결과적으로 혈액 검사 기술의 발전은 혈액 제제의 안전성을 향상시킬 뿐만 아니라 검출 가능한 질병의 범위를 확대하여 예방 의료의 핵심이 되고 있습니다.

혈액 검사 기술의 새로운 트렌드와 혁신이란?

혈액 검사는 보다 종합적이고 신속하며 비용 효율적인 진단 솔루션의 필요성으로 인해 현재 큰 혁신이 진행되고 있습니다. 가장 주목할 만한 트렌드 중 하나는 혈액 검사에 차세대 염기서열 분석기(NGS)의 사용이 확대되고 있다는 점입니다. 이를 통해 유전 물질에 대한 상세한 분석이 가능해져 한 번의 혈액 샘플에서 다양한 병원체와 유전 질환을 식별할 수 있게 되었습니다. 또 다른 새로운 트렌드는 인공지능(AI)과 머신러닝을 혈액 검사 프로세스에 통합하여 기존 방법으로는 놓칠 수 있는 패턴과 이상을 식별하여 진단의 정확도를 높이는 것입니다. 또한, 현장진단(POC) 검사 장비의 개발로 원격지나 자원이 부족한 지역을 포함한 다양한 환경에서 신속한 검사가 가능해져 중요한 진단에 대한 접근성이 개선되면서 혈액 검사는 크게 변화하고 있습니다. 이러한 혁신은 혈액검사의 한계를 뛰어넘어 조기 발견, 보다 맞춤화된 치료 옵션, 환자 예후 개선의 가능성을 제공합니다.

혈액 검사 시장 확대를 촉진하는 요인은 무엇인가?

혈액 검사 시장의 성장은 의료 분야에서 안전하고 정확한 진단의 중요성이 강조되는 몇 가지 중요한 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 특히 의료 인프라가 확대되고 있는 신흥 시장에서 혈액 및 혈액 제제에 대한 수요가 증가하고 있다는 점입니다. 수술, 수혈 및 이식이 증가함에 따라 감염성 질환의 전파를 방지하기 위한 엄격한 혈액 검사의 필요성이 더욱 절실해지고 있습니다. 핵산 검사(NAT)와 차세대 염기서열 분석(NGS)과 같은 기술 발전은 보다 정확하고 효율적인 스크리닝 옵션을 제공함으로써 시장 성장을 가속하고 있습니다. 또한, 만성 질환의 유병률 증가와 조기 발견 및 예방 의학에 대한 관심이 높아지면서 종합적인 혈액 선별 검사에 대한 수요가 증가하고 있습니다. 정부 이니셔티브와 규제에 의해 뒷받침되는 공중보건 기준 개선에 대한 전 세계적인 노력은 혈액 검사 시장의 성장을 더욱 촉진하고 있습니다. 이러한 요인들은 진단 기술의 지속적인 혁신과 함께 현대 의료에서 혈액 검사의 중요한 역할을 강조하고 전 세계 환자의 안전과 복지를 보장하는 데 중요한 역할을 하고 있습니다.

조사 대상 기업 예시(총 12개사)

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols International SA
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.10.07

Global Blood Screening Market to Reach US$3.8 Billion by 2030

The global market for Blood Screening estimated at US$2.6 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Nucleic Acid Test (NAT), one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Enzyme-Linked Immunosorbent Assay (ELISA) segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$697.7 Million While China is Forecast to Grow at 9.1% CAGR

The Blood Screening market in the U.S. is estimated at US$697.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$831.4 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Blood Screening Market - Key Trends and Drivers Summarized

Why Is Blood Screening Essential in Ensuring Safe Healthcare Practices?

Blood screening is a critical process in healthcare, designed to detect infectious agents, genetic disorders, and other health conditions in blood samples before they are used for transfusions, organ transplants, or diagnostic purposes. This screening process is vital to ensuring that blood and blood products are safe for use, thereby preventing the transmission of diseases such as HIV, hepatitis, and syphilis. Blood screening also plays a crucial role in the early detection of conditions like cancer and inherited genetic disorders, allowing for timely intervention and treatment. The accuracy and reliability of blood screening tests are paramount, as they directly impact patient safety and public health. As the demand for safe blood products continues to rise globally, blood screening has become an indispensable component of modern healthcare, protecting patients and ensuring the efficacy of medical treatments.

How Has the Evolution of Technology Transformed Blood Screening Processes?

The field of blood screening has been revolutionized by advancements in technology, leading to faster, more accurate, and comprehensive testing methods. Traditionally, blood screening relied on manual techniques and basic serological tests, which, while effective, were limited in scope and could take days to yield results. The introduction of automated testing systems and molecular diagnostics has drastically improved the speed and accuracy of blood screening. Techniques such as nucleic acid testing (NAT) allow for the detection of viral and bacterial pathogens at a much earlier stage, reducing the risk of transmitting infections through blood transfusions. Additionally, the development of high-throughput screening systems has enabled the processing of large volumes of blood samples more efficiently, which is crucial in meeting the demands of modern healthcare facilities. As a result, the evolution of blood screening technology has not only enhanced the safety of blood products but has also expanded the range of detectable conditions, making it a cornerstone of preventive healthcare.

What Are the Emerging Trends and Innovations in Blood Screening Technology?

Blood screening is currently undergoing significant innovation, driven by the need for more comprehensive, faster, and cost-effective diagnostic solutions. One of the most notable trends is the growing use of next-generation sequencing (NGS) in blood screening, which allows for the detailed analysis of genetic material and the identification of a wide range of pathogens and genetic disorders from a single blood sample. Another emerging trend is the integration of artificial intelligence (AI) and machine learning into blood screening processes, which enhances the accuracy of diagnostics by identifying patterns and anomalies that might be missed by conventional methods. Furthermore, the development of point-of-care (POC) testing devices is transforming blood screening by enabling rapid testing in various settings, including remote and resource-limited areas, thus improving access to critical diagnostics. These innovations are pushing the boundaries of what is possible in blood screening, offering the potential for earlier detection, more personalized treatment options, and improved patient outcomes.

What Are the Factors Fueling Expansion of the Blood Screening Market?

The growth in the blood screening market is driven by several critical factors that underscore the increasing importance of safe and accurate diagnostics in healthcare. One of the primary drivers is the rising demand for blood and blood products, particularly in emerging markets where healthcare infrastructure is expanding. As more surgeries, transfusions, and transplants are performed, the need for rigorous blood screening to prevent the transmission of infectious diseases is becoming more urgent. Technological advancements, such as the adoption of nucleic acid testing (NAT) and next-generation sequencing (NGS), are also fueling market growth by offering more precise and efficient screening options. Additionally, the increasing prevalence of chronic diseases and the growing focus on early detection and preventive care are boosting the demand for comprehensive blood screening tests. The global push for improved public health standards, supported by government initiatives and regulations, is further driving the expansion of the blood screening market. These factors, combined with ongoing innovations in diagnostic technology, highlight the critical role of blood screening in modern healthcare, ensuring the safety and well-being of patients worldwide.

Select Competitors (Total 12 Featured) -

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols International SA
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Blood Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Safe Blood Donations Throws the Spotlight on Advanced Blood Screening Technologies
    • Increasing Incidence of Bloodborne Diseases Drives Demand for Comprehensive Blood Screening Tests
    • Advancements in Molecular Diagnostics Propel Growth in Rapid and Accurate Blood Screening Solutions
    • Shift Toward Early Disease Detection Expands Addressable Market Opportunity for Blood Screening Innovations
    • Innovations in High-Throughput Screening Accelerate Demand for Efficient Blood Testing Systems
    • Expansion of Point-of-Care Diagnostics Spurs Growth in Portable and Rapid Blood Screening Devices
    • Integration of AI in Diagnostics Drives Adoption of Automated Blood Screening Systems
    • Innovations in Sample Collection and Processing Are Enhancing Blood Screening Accuracy
    • Growing Importance of Infection Control Expands Market Penetration for Comprehensive Blood Screening Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blood Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nucleic Acid Test (NAT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Western Blot Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Blood Banks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • JAPAN
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • CHINA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • EUROPE
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • FRANCE
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • GERMANY
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • INDIA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • AFRICA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제